Drug intelligence / Profile preview

Bion3

Development stage: Unknown
Lead developer: Procter & Gamble
Modality: Small Molecules, Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Bion3 is a multi-layered dietary supplement developed by Merck KGaA and currently marketed by P&G. It features a patented triple-layer tablet technology that combines 12 vitamins (including C and D), 7 to 10 minerals (such as zinc and iron), and a proprietary blend of three probiotic strains: *Lactobacillus gasseri* PA 16/8, *Bifidobacterium longum* SP 07/3, and *Bifidobacterium bifidum* MF 20/5. The formulation is specifically designed to support the immune system, maintain a healthy gut flora, and reduce fatigue. By delivering live probiotic cultures alongside essential micronutrients, Bion3 aims to activate the gut's own defense systems and support overall metabolic health.

Brand names: Bion3Bion-3Bion 3
Other names: Bion 3Bion3Bion-3

Beyond the preview

Go deeper on Bion3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bion3.

Explore the full profile